Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01153919 · ClinicalTrials.gov registry record · Phase 2
Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia
A Phase 2 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT01153919 is a Phase 2 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 27 participants.
The verdict
NCT01153919, a Phase 2 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
RATIONALE: Romiplostim may cause the body to make platelets. PURPOSE: This randomized phase II trial is studying how well romiplostim works in treating hepatitis C-infected patients with thrombocytopenia.
Interventions
- OTHER laboratory biomarker analysis
- OTHER placebo
- DRUG ribavirin
- BIOLOGICAL PEG-interferon alfa-2a
- BIOLOGICAL romiplostim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-06-30 |
| Est. Completion | 2018-07-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01153919
The ClinicalTrials.gov registry entry for NCT01153919 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01153919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01153919 about?
NCT01153919 is a clinical study titled "Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia". RATIONALE: Romiplostim may cause the body to make platelets. PURPOSE: This randomized phase II trial is studying how well romiplostim works in treating hepatitis C-infected patients with thrombocytopenia.
What is the current status of trial NCT01153919?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2010-06-30. Estimated completion is 2018-07-14.
What interventions are being tested in trial NCT01153919?
The interventions under investigation include: laboratory biomarker analysis (OTHER), placebo (OTHER), ribavirin (DRUG), PEG-interferon alfa-2a (BIOLOGICAL), romiplostim (BIOLOGICAL).
Who is sponsoring clinical trial NCT01153919?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.